Dr. Oz and FDA chief say biosimilar drug reform will lower prices

Trump administration officials pledged Monday that major reforms for biosimilar drug approvals will expand access and lower prices for some of the most expensive drugs on the market.

Food and Drug Administration Commissioner Marty Makary and Centers for Medicare and Medicaid Services Administrator Mehmet Oz outlined further details about the Trump administration’s plan to slash regulations on biosimilar drug development in an op-ed on Monday .

Recommended Stories

'Lock the clock' movement against seasonal time change gets MAHA boost

Dr. Oz says states spent $1 billion in federal funding on illegal immigrant Medicaid

Illinois legislature passes physician-assisted suicide law and sends it to Pritzker

The administration’s reforms specifically target biologic drugs, or pharmaceut